Results 91 to 100 of about 2,524 (195)

Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case–control study, Spain, 2023/24 season

Eurosurveillance
Background Respiratory syncytial virus (RSV) causes substantial morbidity in infants 
the Nirsevimab Effectiveness Study Collaborators
doaj   +1 more source

Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis

Frontiers in Public Health
BackgroundRespiratory syncytial virus (RSV) causes lower respiratory tract infections (LRTIs) in infants, leading to substantial morbidity and mortality. Nirsevimab, a long-lasting monoclonal antibody, has been demonstrated to reduce RSV-related outcomes
Samira Soudani, Lorenzo Bertizzolo, Mehdi Ghemmouri, Mary Chappell, Rachael McCool, Katie Reddish, Paul Miller, Erin Barker, Harriet Fewster   +8 more
doaj   +1 more source

Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study

International audienceBackgroundNirsevimab, a long-acting monoclonal antibody, has been approved for the prevention of respiratory syncytial virus (RSV) infection in infants.
Morton Fauche, Claire, Derman, Boris, Azemar, Benjamin, Guinard, Jérome, Yab, Emilie, Reslan, Alawyia, Mouna, Lina, Gras-Le Guen, Christele, Flechelles, Olivier, Dossou, Nefert Candace, Brichler, Ségolène, Jatteau, Pierre, Rahou, Yannis, Calvez, Vincent, dos Santos, Georges, Gabassi, Audrey, Fourati, Slim, Plantier, Jean-Christophe, Prot, Matthieu, Legros, Romain, Moreau, Frédérique, Cantais, Aymeric, Bouthry, Elise, Crémadés, Agathe, Gault, Elyanne, Francois, Catherine, Cocherie, Théophile, Boussetta-Charfi, Oulfa, da Silva, Kévin, Schnuriger, Aurélie, Salmona, Maud, Thibault, Vincent, Zemali, Nael, Gaymard, Alexandre, Mnemosyme, Nicolas, Mortamet, Guillaume, Pronier, Charlotte, Bal, Antonin, Bret, Laurent, Avettand-Fenoel, Véronique, Gaitan, Léa, Pawlotsky, Jean-Miichel, Soulié, Cathia, Gallais, Floriane, Bourlet, Thomas, Carcenac, Romain, Simon-Loriere, Etienne, Schwartz, Olivier, Le Goff, Jérôme, Natella, Pierre-André, Staes, Laetitia, Handala, Lynda, Lemoine, Frédéric, Fagour, Laurence, Moisan, Alice, Rogez, Sylvie, Lemoine, Frédérique, Fofana, Djeneba, Ly, Arnaud, Tournegros, Caroline, Rodallec, Audreay, Rachik Abdeljalil, Senhaji, Henry, Steven, Hartard, Cédric, Castain, Louise, Claudet, Isabelle, Audureau, Etienne, Ferrani, Salim, Vallet, Sophie, Castelain, Sandrine, Jeziorski, Eric, Lefeuvre, Caroline, Buchrieser, Julian, Pillet, Sylvie, Veyrenche, Nicolas, Henquell, Cecile, Burrel, Sonia, Mafi, Sarah, Lesne, Fabien, Warnakulasuriya, Fairly, Pilorgé, Léa, Guillaume, Clémence, Jaffar, Marie-Christine, de Pontual, Loic, Bonacorsi, Stéphane, Petat, Hortense, Domitien, Léa, Ader, Mohamed, Regueme, Alexandre, Teyssou, Elisa, Bourret, Jérome, Ouldali, Naim, Foulongne, Vincent, Berreira Ibraim, Samar, Marie, Victoria, Rames, Cinthia, Pawlotsky, Jean-Michel, Tremeaux, Pauline, Enouf, Vincent, Schapira, Anne-Julie, Henry, Amandine, Zekre, Franck, Leveque, Nicolas, Heaugwane, Diana, Rodriguez, Christophe, Zavaoarisaina, Zakasoa-Mbololona, Gaudy-Graffin, Catherine, Vellas, Camille, Perrier, Marine, Néré, Marie-Laure, Vabret, Astrid, Chenafi-Adham, Sara, Le Hingrat, Quentin, Ogoudjobi, Stanislas, Solis, Morgane, Alidjinou, Kazali, Engelmann, Ilka, Rameix-Welti, Marie-Anne, Habib, Mohamed, Marot, Stéphane, Mchantaf, Gilbert, de Oliveira, Anthony, Faisant, Anne, Imbert-Marcille, Berthe-Marie, Gleizes, Eva, Donati, Flora, Deback, Claire, Deroche, Luc, Jeyarajah, Banujaa, Pucelle, Mélanie, Sourice, Justine, Jaffar-Bandjee, Marie-Christine, Soulier, Alexandre, Seng, Sarah, Reslan, Alawiya, Larrat, Sylvie, Souply, Laurent, Pennisi, Alessandra, Kombou, Jose, Aupiais, Camille, Pargny, Vincent, Mirand, Audrey, Cappy, Pierre, Chollet, Lionel, Chauvire-Drouard, Anne, Gardan, Vincent, Bécourt, Arnaud, Casalegno, Jean-Sébastien, Stephan, Valentin, Imbert, Berthe-Marie   +149 more
core   +1 more source

Changes in Respiratory Syncytial Virus‐Associated Hospitalisations Epidemiology After Nirsevimab Introduction in Lyon, France

International audienceBackground Respiratory Syncytial Virus (RSV) is a major health concern, particularly for infants. In France, Nirsevimab, a long‐acting monoclonal antibody to prevent RSV‐associated lower respiratory tract infections (LRTI) was ...
Ploin, Dominique, Butin, Marine, Horvat, Côme, Javouhey, Etienne, Hassenboehler, Juliette, Casalegno, Jean‐sebastien, Gillet, Yves, Plaisant, Franck, Ragouilliaux, Corinne, Nunes, Marta C., Chauvel, Cécile, Chakra, Claire Nour Abou   +11 more
core   +1 more source

Análisis retrospectivo de la epidemiología, gravedad y evolución clínica de la bronquiolitis en la Unidad de Cuidados Intensivos Pediátricos: antes y después de Nirsevimab. [PDF]

Introducción: La introducción de Nirsevimab ha supuesto un cambio en el paradigma de la bronquiolitis por virus respiratorio sincitial (VRS).Objetivos: Analizar la epidemiología, incidencia y gravedad de los pacientes ingresados por bronquiolitis en la ...
Ramos Fuentes, Feliciano, Hernando Larroy, Alicia, García Íñiguez, Juan Pablo   +2 more
core  

Estimating the Public Health and Economic Impact of Immunisation with Nirsevimab or Maternal Immunisation for the Prevention of RSV-Related Outcomes Over Infants’ First RSV Season in the UK

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) poses a significant health burden on infants, particularly during their first RSV season. Immunoprophylactic strategies, such as the administration of nirsevimab, a long-acting monoclonal antibody, have been
Mersha Chetty, Paul Costello, Benjamin Yarnoff, Robert Musci, Mehdi Ghemmouri   +4 more
doaj   +1 more source

Two-season effectiveness of a single nirsevimab dose against RSV hospitalisation in healthy term-born infants: a population-based case–control study, Spain, October 2023 to March 2025

Eurosurveillance
BACKGROUND In autumn 2023, Spain recommended nirsevimab to all infants born after 1 April 2023, as catch-up or at-birth immunisation. AIM We estimated effectiveness of a single nirsevimab dose against respiratory syncytial virus (RSV) hospitalisations ...
the Nirsevimab Effectiveness Study Collaborators
doaj   +1 more source

Nirsevimab and other strategies for the prevention of RSV infection

Anales de Pediatría (English Edition), 2023
Antonio, Iofrío de Arce, Francisco José, Álvarez García   +1 more
openaire   +2 more sources

Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

Human Vaccines & Immunotherapeutics
Nirsevimab has been recently licensed for universal RSV prophylaxis in infants. NIRSE-GAL is a three-year population-based study initiated in Galicia in September 2023.
Narmeen Mallah, Sonia Ares-Gómez, Jacobo Pardo-Seco, Alberto Malvar-Pintos, María-Isolina Santiago-Pérez, Olaia Pérez-Martínez, María-Teresa Otero-Barrós, Nuria Suárez-Gaiche, Rolf Kramer, Jing Jin, Leticia Platero-Alonso, Rosa-María Alvárez-Gil, Olga-María Ces-Ozores, Victoria Nartallo-Penas, Susana Mirás-Carballal, Marta Piñeiro-Sotelo, Juan-Manuel González-Pérez, Carmen Rodríguez-Tenreiro, Irene Rivero-Calle, Antonio Salas, Carmen Durán-Parrondo, Federico Martinón-Torres   +21 more
doaj   +1 more source

Efficacy and safety of a single dose of nirsevimab against respiratory syncytial virus infection in infants: a meta-analysis and time-to-event analysis

Italian Journal of Pediatrics
Respiratory syncytial virus (RSV) is one of the causes of lower respiratory tract infections (LRTIs) and related hospitalizations in neonates and infants.
Mohamed Saad Sayed, Mena Ayman Elgendy, Nada Gamil, Hossam Hassan Abdullah, Alaa Alhwary, Rahma Abdulfattah Ibrahim, Sama Hesham Samir, Nada S. Jibril, Hebatullah Abdulazeem, Mohammed Alsabri   +9 more
doaj   +1 more source